Targeted genotyping revealed that 95% of papillary craniopharyngiomas had BRAFV600E mutations, and 96% of ameloblastic craniopharyngiomas had CTNNB mutations suggesting that molecular targeted therapy for craniopharyngiomas may be effective (130). Here, CTNNB1 is linked to craniopharyngioma.